258 related articles for article (PubMed ID: 31792037)
1. Linsitinib (OSI-906) for the Treatment of Adult and Pediatric Wild-Type Gastrointestinal Stromal Tumors, a SARC Phase II Study.
von Mehren M; George S; Heinrich MC; Schuetze SM; Yap JT; Yu JQ; Abbott A; Litwin S; Crowley J; Belinsky M; Janeway KA; Hornick JL; Flieder DB; Chugh R; Rink L; Van den Abbeele AD
Clin Cancer Res; 2020 Apr; 26(8):1837-1845. PubMed ID: 31792037
[TBL] [Abstract][Full Text] [Related]
2. SDHA loss of function mutations in a subset of young adult wild-type gastrointestinal stromal tumors.
Italiano A; Chen CL; Sung YS; Singer S; DeMatteo RP; LaQuaglia MP; Besmer P; Socci N; Antonescu CR
BMC Cancer; 2012 Sep; 12():408. PubMed ID: 22974104
[TBL] [Abstract][Full Text] [Related]
3. Gastrointestinal stromal tumors - Summary of mutational status of the primary/secondary KIT/PDGFRA mutations, BRAF mutations and SDH defects.
Kalfusova A; Linke Z; Kalinova M; Krskova L; Hilska I; Szabova J; Vicha A; Kodet R
Pathol Res Pract; 2019 Dec; 215(12):152708. PubMed ID: 31708372
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of insulin-like growth factor 1 receptor and frequent mutational inactivation of SDHA in wild-type SDHB-negative gastrointestinal stromal tumors.
Belinsky MG; Rink L; Flieder DB; Jahromi MS; Schiffman JD; Godwin AK; von Mehren M
Genes Chromosomes Cancer; 2013 Feb; 52(2):214-24. PubMed ID: 23109135
[TBL] [Abstract][Full Text] [Related]
5. Molecular Subtypes of KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Gastrointestinal Stromal Tumor Clinic.
Boikos SA; Pappo AS; Killian JK; LaQuaglia MP; Weldon CB; George S; Trent JC; von Mehren M; Wright JA; Schiffman JD; Raygada M; Pacak K; Meltzer PS; Miettinen MM; Stratakis C; Janeway KA; Helman LJ
JAMA Oncol; 2016 Jul; 2(7):922-8. PubMed ID: 27011036
[TBL] [Abstract][Full Text] [Related]
6. Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy.
Ben-Ami E; Barysauskas CM; von Mehren M; Heinrich MC; Corless CL; Butrynski JE; Morgan JA; Wagner AJ; Choy E; Yap JT; Van den Abbeele AD; Solomon SM; Fletcher JA; Demetri GD; George S
Ann Oncol; 2016 Sep; 27(9):1794-9. PubMed ID: 27371698
[TBL] [Abstract][Full Text] [Related]
7. Good survival outcome of metastatic SDH-deficient gastrointestinal stromal tumors harboring SDHA mutations.
Pantaleo MA; Lolli C; Nannini M; Astolfi A; Indio V; Saponara M; Urbini M; La Rovere S; Gill A; Goldstein D; Ceccarelli C; Santini D; Rossi G; Fiorentino M; Di Scioscio V; Fusaroli P; Mandrioli A; Gatto L; Catena F; Basso U; Ercolani G; Pinna AD; Biasco G
Genet Med; 2015 May; 17(5):391-5. PubMed ID: 25188872
[TBL] [Abstract][Full Text] [Related]
8. Analysis of all subunits, SDHA, SDHB, SDHC, SDHD, of the succinate dehydrogenase complex in KIT/PDGFRA wild-type GIST.
Pantaleo MA; Astolfi A; Urbini M; Nannini M; Paterini P; Indio V; Saponara M; Formica S; Ceccarelli C; Casadio R; Rossi G; Bertolini F; Santini D; Pirini MG; Fiorentino M; Basso U; Biasco G;
Eur J Hum Genet; 2014 Jan; 22(1):32-9. PubMed ID: 23612575
[TBL] [Abstract][Full Text] [Related]
9. Gene expression of the IGF pathway family distinguishes subsets of gastrointestinal stromal tumors wild type for KIT and PDGFRA.
Beadling C; Patterson J; Justusson E; Nelson D; Pantaleo MA; Hornick JL; Chacón M; Corless CL; Heinrich MC
Cancer Med; 2013 Feb; 2(1):21-31. PubMed ID: 24133624
[TBL] [Abstract][Full Text] [Related]
10. Succinate dehydrogenase-deficient GISTs are characterized by IGF1R overexpression.
Chou A; Chen J; Clarkson A; Samra JS; Clifton-Bligh RJ; Hugh TJ; Gill AJ
Mod Pathol; 2012 Sep; 25(9):1307-13. PubMed ID: 22555179
[TBL] [Abstract][Full Text] [Related]
11. A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib.
Ganjoo KN; Villalobos VM; Kamaya A; Fisher GA; Butrynski JE; Morgan JA; Wagner AJ; D'Adamo D; McMillan A; Demetri GD; George S
Ann Oncol; 2014 Jan; 25(1):236-40. PubMed ID: 24356634
[TBL] [Abstract][Full Text] [Related]
12. Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033.
Heinrich MC; Rankin C; Blanke CD; Demetri GD; Borden EC; Ryan CW; von Mehren M; Blackstein ME; Priebat DA; Tap WD; Maki RG; Corless CL; Fletcher JA; Owzar K; Crowley JJ; Benjamin RS; Baker LH
JAMA Oncol; 2017 Jul; 3(7):944-952. PubMed ID: 28196207
[TBL] [Abstract][Full Text] [Related]
13. ACRIN 6665/RTOG 0132 phase II trial of neoadjuvant imatinib mesylate for operable malignant gastrointestinal stromal tumor: monitoring with 18F-FDG PET and correlation with genotype and GLUT4 expression.
Van den Abbeele AD; Gatsonis C; de Vries DJ; Melenevsky Y; Szot-Barnes A; Yap JT; Godwin AK; Rink L; Huang M; Blevins M; Sicks J; Eisenberg B; Siegel BA
J Nucl Med; 2012 Apr; 53(4):567-74. PubMed ID: 22381410
[TBL] [Abstract][Full Text] [Related]
14. Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group.
Patrikidou A; Domont J; Chabaud S; Ray-Coquard I; Coindre JM; Bui-Nguyen B; Adenis A; Rios M; Bertucci F; Duffaud F; Chevreau C; Cupissol D; Pérol D; Emile JF; Blay JY; Le Cesne A;
Eur J Cancer; 2016 Jan; 52():173-80. PubMed ID: 26687836
[TBL] [Abstract][Full Text] [Related]
15. A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17.
Yeh CN; Chen MH; Chen YY; Yang CY; Yen CC; Tzen CY; Chen LT; Chen JS
Oncotarget; 2017 Jul; 8(27):44121-44130. PubMed ID: 28487491
[TBL] [Abstract][Full Text] [Related]
16. Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study.
Kang YK; George S; Jones RL; Rutkowski P; Shen L; Mir O; Patel S; Zhou Y; von Mehren M; Hohenberger P; Villalobos V; Brahmi M; Tap WD; Trent J; Pantaleo MA; Schöffski P; He K; Hew P; Newberry K; Roche M; Heinrich MC; Bauer S
J Clin Oncol; 2021 Oct; 39(28):3128-3139. PubMed ID: 34343033
[TBL] [Abstract][Full Text] [Related]
17. [Clinicopathological features and prognosis of gastrointestinal stromal tumors with
Shen YY; Li XQ; Yang LX; Fang Y; Nie MM; He ZR; Hou YY; Cao H; Wang M; Shen KT
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Sep; 24(9):804-813. PubMed ID: 34530562
[No Abstract] [Full Text] [Related]
18. Immunohistochemical loss of succinate dehydrogenase subunit A (SDHA) in gastrointestinal stromal tumors (GISTs) signals SDHA germline mutation.
Miettinen M; Killian JK; Wang ZF; Lasota J; Lau C; Jones L; Walker R; Pineda M; Zhu YJ; Kim SY; Helman L; Meltzer P
Am J Surg Pathol; 2013 Feb; 37(2):234-40. PubMed ID: 23282968
[TBL] [Abstract][Full Text] [Related]
19. Expression of IGF-1 receptor in KIT/PDGF receptor-α wild-type gastrointestinal stromal tumors with succinate dehydrogenase complex dysfunction.
Nannini M; Astolfi A; Paterini P; Urbini M; Santini D; Catena F; Indio V; Casadio R; Pinna AD; Biasco G; Pantaleo MA
Future Oncol; 2013 Jan; 9(1):121-6. PubMed ID: 23252569
[TBL] [Abstract][Full Text] [Related]
20. Identifying Secondary Mutations in Chinese Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs) by Next Generation Sequencing (NGS).
Du J; Wang S; Wang R; Wang SY; Han Q; Xu HT; Yang P; Liu Y
Pathol Oncol Res; 2020 Jan; 26(1):91-100. PubMed ID: 31758409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
